WallStreetZenWallStreetZen

NASDAQ: EVAX
Evaxion Biotech A Stock Forecast, Predictions & Price Target

Analyst price target for EVAX

Based on 1 analyst offering 12 month price targets for Evaxion Biotech A.
Min Forecast
$14.00+366.67%
Avg Forecast
$14.00+366.67%
Max Forecast
$14.00+366.67%

Should I buy or sell EVAX stock?

Based on 1 analyst offering ratings for Evaxion Biotech A.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EVAX stock forecasts and price targets.

EVAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-20

1 of 1

Forecast return on equity

Is EVAX forecast to generate an efficient return?

Forecast return on assets

Is EVAX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

EVAX revenue forecast

What is EVAX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$14.0M+19,078.08%
Avg 2 year Forecast
$72.1M+98,697.26%
Avg 3 year Forecast
$85.0M+116,361.64%
EVAX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EVAX revenue growth forecast

How is EVAX forecast to perform vs Biotechnology companies and vs the US market?
Company
982.33%
Industry
38.94%
Market
10.52%
EVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EVAX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EVAX$3.00$14.00+366.67%Buy
ATHE$2.02$4.00+98.02%Buy
BCDA$0.42$4.00+854.65%Buy
IBIO$3.36N/AN/A
MNPR$0.74N/AN/A

Evaxion Biotech A Stock Forecast FAQ

Is Evaxion Biotech A Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: EVAX) stock is to Buy EVAX stock.

Out of 1 analyst, 0 (0%) are recommending EVAX as a Strong Buy, 1 (100%) are recommending EVAX as a Buy, 0 (0%) are recommending EVAX as a Hold, 0 (0%) are recommending EVAX as a Sell, and 0 (0%) are recommending EVAX as a Strong Sell.

If you're new to stock investing, here's how to buy Evaxion Biotech A stock.

What is EVAX's revenue growth forecast for 2024-2026?

(NASDAQ: EVAX) Evaxion Biotech A's forecast annual revenue growth rate of 982.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Evaxion Biotech A's revenue in 2024 is $73,000.On average, 1 Wall Street analysts forecast EVAX's revenue for 2024 to be $530,568,920, with the lowest EVAX revenue forecast at $530,568,920, and the highest EVAX revenue forecast at $530,568,920. On average, 1 Wall Street analysts forecast EVAX's revenue for 2025 to be $2,733,263,689, with the lowest EVAX revenue forecast at $2,733,263,689, and the highest EVAX revenue forecast at $2,733,263,689.

In 2026, EVAX is forecast to generate $3,221,955,562 in revenue, with the lowest revenue forecast at $3,221,955,562 and the highest revenue forecast at $3,221,955,562.

What is EVAX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: EVAX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is EVAX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EVAX price target, the average EVAX price target is $14.00, with the highest EVAX stock price forecast at $14.00 and the lowest EVAX stock price forecast at $14.00.

The Wall Street analyst predicted that Evaxion Biotech A's share price could reach $14.00 by Mar 20, 2025. The average Evaxion Biotech A stock price prediction forecasts a potential upside of 366.67% from the current EVAX share price of $3.00.

What is EVAX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: EVAX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.